News

Fortis-M is a global, multicenter, randomised, double-blind, placebo-controlled phase 3 trial. It evaluates oral Talactoferrin plus best supportive care compared to placebo, plus best supportive care in patients

The authors report in the publication that the primary endpoint and key secondary endpoints of the Clarity trial were met. The Clarity data were presented at the 61st

Jean-Michel Halfon, president of emerging-markets business at Pfizer, said that the drug maker intends to increase its sales force from 2,300 in approxiamtely 180 cities to about 3,200

The company’s conversion to EcoGuard packaging will keep more than six million plastic bottles from ending up in oceans, natural habitats and landfills each year, claims Rainbow Light.

UshStat is designed to deliver a corrected version of the MYO7A gene into the cells of the retina, using the company’s LentiVector gene delivery technology. In collaboration with

Victoza is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan.It is indicated as monotherapy or as an add-on to sulphonylurea (SU) in

The approval of Aloxi is based on the compelling results of a large multicenter randomized double-blind clinical trial (Protect study) conducted in Japan, which demonstrated the superiority of

The study suggested that ICT-107, which targets those antigens, may target not only the cells that make up the bulk of certain cancerous tumors, but also the CSCs

CHK1 is a key component of a biochemical pathway responsible for reducing the effectiveness of traditional cancer therapeutics such as chemotherapy. The collaboration has developed novel, potent and